GOVERNANCE Compensations Facebook Twitter LinkedIn Compensations of Executive Directors Addendum to the Report on compensation of corporate officers Details of compensation arrangements for Executive Directors, March 3, 2021 Clarifications on the compensation of the Chief Executive Officer Details of compensation arrangements for Executive Directors, March 4, 2020 Details of compensation arrangements for Executive Directors, March 8, 2019 Details of compensation arrangements for Executive Directors, March 6, 2018 Details of compensation arrangements for Executive Directors, March 3, 2017 Details of compensation arrangements for Executive Directors, March 3, 2016 Details of compensation arrangements for Executive Directors, March 3, 2015 Commitments in favor of Executive Directors Information on the final terms of departure of Olivier Brandicourt, former CEO, April 28, 2020 Information on the conditions for the departure from office of Mr. Olivier Brandicourt, March 4, 2020 Commitments in favor of Mr. Olivier Brandicourt, July 26, 2019 Commitments in favor of Mr. Paul Hudson, June 7, 2019 Commitments in favor of Mr. Olivier Brandicourt, February 7, 2017 Commitments in favor of Mr. Olivier Brandicourt, February 19, 2015 Commitments in favor of Mr. Christopher Viehbacher, January 22, 2015 Equity Compensation – CEO & Employees In 2019, the Board of Directors reviewed its policy on equity compensation, which is a reserved power, and decided not to grant any more stock options from 2020 onwards. It wished to standardize the conditions for granting shares to the Board of Directors within the group. Therefore, equity compensation is made up of performance shares only both for the employees and the Chief Executive Officer. It serves to align employee and shareholder interests and reinforce employees’ ties to the Company. All performance shares granted are subject in their entirety to the achievement of multi-year performance criteria. The plans put in place by the Board of Directors in 2019, 2020 and 2021 are conditioned, for employees (except the Chief Executive Officer and Senior Executives, i.e. around 6,000 beneficiaries in 2021) on two internal performance criteria based on the Net Result of Activities and Free Cash Flow (FCF) and, for the Chief Executive Officer and around 450 Senior Executives, on the two aforementioned performance criteria and on a third external criterion (Total Shareholder Return compared to a panel of pharmaceutical companies). The Board of Directors commits to report to its shareholders on the level of performance achieved under these conditions in Sanofi's annual reports (Universal Registration Document and U.S. Form 20-F). For additional information concerning the equity compensation policies of the Board of Directors, please refer to the following documents: 2021 2021 Performance Shares Plan - 13I 2021 Performance Shares Plan - 13I/EX 2020 2020 Performance Shares Plan - 12I 2020 Performance Shares Plan - 12I/EX 2019 2019 Performance Shares Plan CEO Stock Option and Performance Shares for 2019 2018 2018 Performance Shares Plan TSR Explanation for 2018 Plans 2017 2017 Stock Subscription Option Plan 2017 Performance Shares Plan TSR Explanation for 2017 Plans 2016 2016 Stock Subscription Option Plan 2016 Performance Shares Plan TSR Explanation for 2016 Plans 2015 2015 Stock Subscription Option Plan 2015 Performance Shares Plan TSR Explanation for 2015 Plans Follow us Sanofi on Twitter Sanofi TV on YouTube Sanofi On LinkedIn Sanofi on Instagram Sanofi RSS feeds Contact Legal notice Privacy & Data Protection Cookies policy Corporate code of ethics Our publications Sitemap Our websites Accessibility: partial compliance © Sanofi 2004-2021 - All rights reserved